Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring. Issue 10 (1st March 2022)

• Record Type: Journal Article
• Authors: Lai, Francisco Tsz Tsun; Leung, Miriam Tim Yin; Chan, Edward Wai Wa; Huang, Lei; Lau, Lauren Ka Wun; Peng, Kuan; Leung, Janice Ching Nam; Fan, Min; Chen, Kailin; Lum, Dawn Hei; Li, Xue; Chui, Celine Sze Ling; Wan, Eric Yuk Fai; Wong, Carlos King Ho; Lam, Edwin Fung Shing; Cheung, Terence Yung Yan; Cowling, Benjamin John; Wong, Ian Chi Kei; Chan, Esther Wai Yin
• Is Part Of: Vaccine. Volume 40:Issue 10(2022)
• Page Start: 1390
• Page End: 1396
• Publication Date: 2022-03-01
• Subjects: Community vaccination center -- Covid-19 -- Multimorbidity -- Pain -- SARS-CoV-2 -- Severe allergic reactions -- Systemic reactions; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.01.062
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Objective: CoronaVac (Sinovac) Covid-19 vaccine has recently been approved for emergency use by the World Health Organization. However, data on its reactogenicity in real-world settings is scant. This study aimed to compare self-reported post-vaccination adverse reactions between CoronaVac and Comirnaty (Pfizer-BioNTech). Methods: We adopted a prospective cohort study design using online surveys from the day of first-dose vaccination with intensive follow-up through two weeks after the second dose (11 time points). The primary outcome was adverse reactions (any versus none) and secondary outcomes were the sub-categories of adverse reactions (local, systemic, and severe allergic reactions). Potential effect modification across multimorbidity status, older age, and sex was examined. Results: In total, 2, 098 participants who were scheduled to complete the 14th-day survey were included, with 46.2% receiving Comirnaty. Retention rate two weeks after the second dose was 81.0% for the CoronaVac group and 83.6% for the Comirnaty group. Throughout the follow-up period, 801 (82.7%) of those receiving Comirnaty and 543 (48.1%) of those receiving CoronaVac reported adverse reactions. Adjusted analysis suggested that compared with Comirnaty, CoronaVac was associated with 83%-reduced odds of any adverse reactions [adjusted odds ratio (AOR) = 0.17, 95% confidence interval (CI) 0.15–0.20], 92%-reduced odds of local adverse reactions (AOR = 0.08, 95% CI 0.06–0.09), and 76%-reduced odds of systemic adverse reactions (AOR = 0.24, 95% CI 0.16–0.28). No significant effect modification was identified. Conclusion: This post-marketing study comparing the reactogenicity of Covid-19 vaccines suggests a lower risk of self-reported adverse reactions following vaccination with CoronaVac compared with Comirnaty.